ABSTRACT. Group B streptococcus (GBS), a common neonatal gram-positive pathogen, causes similar pathophysiology in human newborns and neonatal animal models of sepsis. Animal models of GBS sepsis demonstrate a two-phase response: 1 ) an acute phase (<I h) of increased pulmonary artery pressure (P,,) and reduced arterial oxygen pressure (Pao2) that is associated with increased serum thromboxane Bz (TxB2) and 2) a late phase (2-4 h) of persistently increased P,, and reduced Paoz, reduced systemic arterial pressure, and progressive fall in cardiac output that is associated with increased serum TxB2, 6-keto-prostaglandin F1, (6-keto-PGF,,), and tumor necrosis factor-a (TNF,). We hypothesized that pretreatment of piglets with both pentoxifylline (PTF), an inhibitor of TNF, production and activity, and indomethacin (INDO) would 1 ) inhibit GBS-induced TxB2, 6-keto-PGF,,, and TNF, and 2) prevent both the acute-and late-phase physiologic responses of GBS sepsis. Combined PTF and INDO pretreatment of anesthetized, mechanically ventilated piglets infused with GBS (1.25 x lo9 colony forming units/ kglh) for 4 h prevented GBS-induced increases in P,, at 1 h (GBS+PTF+INDO: 1.8 f 0.07 kPa versus GBS alone: 4.7 f 0.1 kPa) and markedly attenuated increases in P,, at 4 h (GBS+PTF+INDO: 2.1 f 0.1 kPa versus GBS alone: 4.4 f 0.1 kPa). PTF+INDO treatment prevented GBS-induced reductions in both mixed venous oxygen pressure and Paoz at 1, 2, and 4 h (GBS+PTF+INDO: 11.5 2 0.4 kPa versus GBS alone: 7.1 f 0.4 kPa), and attenuated GBS-induced declines in .cardiac output. PTF+INDO treatment significantly attenuated GBS-induced serum TNF, polypeptide levels (ELISA, pg/mL) at 4 h (GBS+PTF+INDO: 143 f 45 versus GBS alone: 502 f 147) and blocked GBS-induced increases in serum TxBz and 6-keto-PGR, (all levels < 10 pg1O.l mL by RIA).
GBS sepsis in human neonates is associated with hypoxemia, pulmonary hypertension, shock, and high mortality (1) (2) (3) . Neonatal animal models of i.v. GBS infusion show similar features, but with the delineation of both an acute and late phase response (4, 5) . Acute features (<1 h) include pulmonary hypertension, hypoxemia, and reduced CO. The acute phase of GBS infusion in animals is associated with increased serum TxB2 levels, a stable metabolite of the potent vasoconstrictor TxA2 (5, 6) .
Inhibition of TxA2 synthesis by indomethacin (INDO), a cyclooxygenase inhibitor, or dazmegrel, a thromboxane synthase inhibitor, prevents the acute pulmonary hypertension and hypoxemia of GBS bacteremia in piglets (5, 6) . Dimethylthiourea also attenuates GBS-induced acute pulmonary hypertension and hypoxemia in piglets, suggesting that hydroxyl radicals contribute to the acute features of GBS sepsis (7) .
The late features (2-4 h) of GBS infusion in animal models include persistent pulmonary hypertension, hypoxemia, progressive fall in CO, systemic hypotension, and lung injury (4) (5) (6) . The late phase of GBS infusion is associated with increased serum levels of TxB2, 6-keto-PGF,,, a stable metabolite of the potent vasodilator PGI2, and TNF, (5, 6, 8, 9) . Early INDO administration blocks the late phase increase in both serum TxBz and 6-keto-PGF,, (5) , but serum TNF, levels were not measured in these studies. INDO treatment causes little improvement in late phase GBS-induced pulmonary hypertension (5), but partially attenuates late phase GBS-induced systemic hypotension, reduced CO, and hypoxemia (5) . PTF, a methylxanthine that inhibits TNF, production and activity (10-1 5) , significantly reduces GBS-induced serum TNF, polypeptide levels in neonatal piglets, but does not inhibit GBS-induced TxA2 or PGI2 produc-COMBINED PTF AND INDO IN GBS SEPSIS 223 tion (8) . However, PTF causes only a mild improvement in GBSinduced late-phase pulmonary hypertension and hypoxemia in piglets (8) . These combined observations show that neither treatment with INDO nor PTF alone causes marked improvement in the late phase of GBS infusion in piglets. We speculate that arachidonic acid metabolites and TNF, may act in an additive or synergistic manner to contribute to the late-phase features of GBS sepsis.
We hypothesized that combined PTF and INDO pretreatment would inhibit GBS-induced TxA2, PGI2, and TNF, production and would prevent both the acute and late phase pathophysiologic responses of GBS sepsis in neonatal piglets.
MATERIALS AND METHODS
Animal preparation. Twenty piglets were anesthetized (30 mg/ kg pentobarbital i.v.), paralyzed (0.3 mg/kg pancuronium bromide i.v.), anticoagulated with heparin (1000 IU i.v.), and mechanically ventilated via a tracheostomy tube with a large animal Harvard ventilator adjusted to deliver a tidal volume of 12 + 2 mL/kg at a rate to maintain arterial carbon dioxide pressure at 4.6 to 5.3 kPa (35-40 mm Hg) during baseline conditions. The piglets from each experimental group were of similar age and weight: GBS alone, 3.1 k 0.5 kg, 12 + 2 d of age; GBS+INDO, 3.5 + 8 kg, 13 k 2 d of age; GBS+PTF+INDO, 3.6 + 0.7 kg, 12 + 2 d of age. All animals were ventilated with room air throughout each experiment. As previously described (l6), catheters were placed in I ) the left external jugular vein for infusion of GBS, PTF, or INDO (double lumen 5 Fr Swan-Ganz, American Edwards Laboratories, Irvine, CA), 2) the aorta to measure P, and sample arterial blood for pH, blood gas tensions, and eicosanoid and TNF, measurements, and 3) a branch of the left pulmonary artery (5 Fr Swan-Ganz thermodilution catheter) to measure P,, and P, and CO in triplicate by thermodilution using an Edwards 9520A CO computer (American Edwards Laboratories) and for sampling mixed venous blood. After instrumentation, anesthesia and muscle paralysis were maintained with pentobarbital (3 mg/ kg i.v. every h) and pancuronium bromide (3 mg/kg i.v. every h), respectively. The piglets received sigh breaths to 30 cm H 2 0 every 20 min to minimize spontaneous development of atelectasis. Vascular pressures were measured using Hewlett-Packard 1280 transducers (Hewlett-Packard Co., Palo Alto, CA) referenced to mid-chest. Core temperature was maintained at 38.5 + 0.5"C with an overhead radiant heat source.
GBS strain and preparation. The GBS strain is a type I11 clinical isolate made rifampin-and streptomycin-resistant (COH 31 r/s) (16) . The culture conditions, mode of resuspension in sterile nonbacteriostatic saline, and tests of culture purity were performed as described (17) . The GBS suspensions for infusion into piglets contained C0.03 endotoxin units/mL of endotoxin based on the limulus amebocyte lysate assay (5 endotoxin units/ mL = 1 ng/mL) (Associates of Cape Cod, Woods Hole, MA).
Eicosanoid assays. Two-mL arterial blood samples were obtained under each of the four experimental conditions. The blood samples were drawn into cold inhibitor solution containing indomethacin and sodium EDTA and centrifuged as previously described (9) . The decanted plasma was frozen at -70°C until RIA for TxB2 and 6-keto-PGF1, were performed as described (9) . TxB2 and 6-keto-PGF,, were assayed by measuring competitive inhibition of [3H]T~B2 to rabbit anti-TxB2 binding or [3H]6-keto-PGFI, to anti-6-keto-PGF1,, respectively (9) . The average of duplicate assays was used to determine group means for the different experimental conditions. The limit of detection for TxB2 and 6-keto-PGF,, was <10 pg/O.l mL. Matrix effects due to protein present in piglet plasma were measured in standard curves using eicosanoid-free piglet plasma prepared by charcoal stripping (9) . TNF, ELISA assay. Two-mL arterial blood samples were obtained under each of the four experimental conditions for each piglet. The samples were stored on ice during the protocol and then centrifuged at 15 000 rpm x 15 min. The decanted serum was frozen and stored at -70°C until a TNF, ELISA assay was performed in duplicate. A human TNF, serum ELISA kit was kindly provided by Genentech, Inc., San Francisco, CA. This "sandwich" ELISA assay used rabbit anti-TNFa coat antibody (Genentech, Inc., Lot 470 1-92) and horseradish peroxidase-conjugated mouse monoclonal anti-TNF, (Genentech, Inc., Lot 4707-25), as described (8) . A human recombinant TNF, (Genentech, Inc., Lot TH151A) standard curve was prepared over the range of 35 to 2000 pg/mL in PBS containing BSA (5 mg/mL). A relationship between OD at 490 nm and TNF, concentration is derived from the standard curve by linear regression. The piglet serum TNF, levels were derived by interpolation from the average of the two assays. The limit of TNF, detection by our assay was <35 pg/mL.
Experimental design. After instrumentation, each piglet received 10 mL/kg 0.9% saline i.v. to ensure a standardized euvolemic state. Data from three groups of piglets are reported: Group 1 (GBS alone), in which seven piglets received saline (2 mL/kg i.v. bolus, followed by saline infusion at 2 mL/kg/h) and 30 min later received i.v. GBS at 1.25 x lo9 cfu/kg/h for 4 h; Group 2 (GBS+INDO), in which six piglets received INDO [3 mg/kg i.v. bolus (1 mL/kg), followed by 0.9% saline infusion at 2 mL/kg/h] and 30 min later received i.v. GBS at 1.25 x lo9 cfu/kg/h for 4 h; and Group 3 (GBS+PTF+INDO), in which seven piglets received i.v. PTF (20 mg/kg i.v. bolus followed by 20 mg/kg/h infusion) and INDO (3 mg/kg i.v.) and 30 min later received i.v. GBS at 1.25 x lo9 cfu/kg/h for 4 h. Piglets infused with 0.9% saline or PTF (20 mg/kg bolus, then 20 mg/kg/h) alone showed no significant physiologic abnormalities and no significant increases in TxB2, 6-keto-PGFl,, or TNF, (8) .
In each piglet, Ppa, P,, P, , CO, arterial and mixed venous blood gas tensions, and arterial blood samples for measurement of TxB2, 6-keto-PGFI,, and TNF, were obtained at baseline (PRE) and at 1, 2, and 4 h. PVR (Ppa -P,/CO) and SVR (P,/CO) were calculated at the same time points for each piglet.
Statistical analysis. Analysis of variance with Student-Neuman-Keuls correction for multiple comparisons was used to compare values between the experimental groups; paired t tests were used to compare intragroup values (SPSS/PC+ v3.0, SPSS, Inc., Chicago, IL). A p value of <0.05 was considered significant. three experimental groups ( Table 2 ). The PVR/SVR ratio increased from baseline at 1, 2, and 4 h in the GBS alone piglets. INDO pretreatment prevented an increase in the PVR/SVR
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ratio at 1 h, but not at 2 or 4 h, where values were similar to those of GBS alone piglets. PTF+INDO treatment prevented a significant increase in the PVR/SVR ratio at 1 h and significantly attenuated the increase in PVR/SVR ratio at 4 h compared with GBS and GBS+INDO piglets.
Gas exchange. Table 3 shows the blood gas values for each group of piglets during the 4-h infusions. INDO treatment prevented the fall in Pao2 at 1 and 2 h, and Pao2 at 4 h was 2.7 significantly improved in GBS+INDO compared with GBS alone piglets. However, Pao2 at 4 h was significantly decreased from baseline values in GBS+INDO piglets. PTF+INDO treatment resulted in no significant decrease in Pao2 at 1, 2, and 4 h. The 0
4 h Pao2 at 4 h was significantly improved in GBS+PTF+INDO piglets compared with the 4-h Paol in the other two groups. but INDO and PTF+INDO treatment prevented the development of significant metabolic acidosis (pH < 7.35). The calcuacute increases in p,, and PVR, but resulted in no improvement lated base excess at baseline was similar for the three groups in P,, or PVR at 4 h in GBS+INDO compared with GBS alone (GBS: 2 f 0.8, GBS+INDO: 2 +: 1.1, GBS+PTF+INDO: 1.5 +: piglets. PTF+INDO pretreatment prevented the GBS-induced 0.9)-However, both INDO and PTF+INDO treatment attenacute increases in p,, and pVR and markedly attenuated the uated the GBS-induced decline in base excess at 4 h (GBS: 7 f increase in P,, and PVR at 4 h compared with the other two 1.1, GBS+INDO:
groups of piglets ( p < 0.05).
Eicosanoids. Figures 3A and 3B depict changes in serum TxB2 Systemic hemodynamics. Table 1 shows the changes in CO, and 6-keto-PGF1, levels, respectively, for each group of piglets. P, , and SVR for each group of piglets during the 4-h infusions. INDO and PTF+INDO treatment prevented GBS-induced in-INDO pretreatment did not improve CO at 1 h or 4 h in creases in serum TxB2 or 6-keto-PGF,, at 1, 2, and 4 h. Serum GBS+INDO compared with GBS alone piglets. PTF+INDO TxB2 and 6-keto-PGF1, levels were < 10 pg/O.l mL at all time pretreatment prevented the acute fall in CO and significantly points for these two groups of piglets. improved CO compared with the other two groups at 1 and 2 h; Tumor necro~i~factor. Figure 4 depicts changes in serum TNF, PTF+INDO pretreatment significantly improved CO at 4 h in polypeptide levels in each group of piglets. INDO pretreatment GBS+PTF+INDO piglets compared with the other two groups did not significantly reduce GBS-induced serum TNF, poly-( p < 0.05).
peptide levels at 1, 2 and 4 h in GBS+INDO compared with P,, was not significantly reduced at 1 and 2 h of infusion in GBS alone piglets. PTF+INDO treatment attenuated GBSany of the groups; P, was significantly reduced at 4 h in GBS induced serum TNF, polypeptide levels at both 2 and 4 h in alone and GBS+PTF+INDO piglets. Piglets infused with GB+PTF+INDO compared with GBS alone piglets. GBS+INDO showed no significant fall in P, at 4 h. INDO treatment, but not combined PTF+INDO treatment, attenuated DISCUSSION the GBS-induced decrease in P, at 4 h. SVR increased significantly from baseline at 1, 2, and 4 h in Pentoxifylline and indomethacin pretreatment of piglets in-GBS alone and at 2 and 4 h in GBS+INDO piglets; SVR did not fused with GBS caused significantly greater improvement in latesignificantly change from baseline at 1, 2, or 4 h in phase pulmonary hemodynamic and gas exchange indices com-GBS+PTF+INDO piglets (Table 1) .
pared with piglets treated with INDO alone. PTF+INDO treatRatio of pulmonary vascular resistance to systemic vascular ment of GBS sepsis in piglets also resulted in greater hemodyresistance. The PVR/SVR ratio was similar at baseline for the namic and gas exchange improvement compared with historical controls treated with PTF alone (8) . PTF+INDO and PTF pretreatment alone resulted in similar reductions in GBS-induced serum TNF, levels (8) , but the combined treatment blocked GBS-induced thromboxane and prostacyclin production (8) . PTF treatment of GBS sepsis caused augmentation of prostacyclin production (8) . The inhibition of prostacyclin production by PTF+INDO may have improved both the late-phase gas exchange and hemodynamic responses compared with PTF treatment alone (8) . In contrast to PTF+INDO treatment, INDO pretreatment alone did not significantly improve late-phase GBSinduced pulmonary hypertension, or late-phase decline in CO.
Our findings are similar to those of Runkle et al. (5) in which piglets were treated with INDO (3 mglkg) 15 min after the onset of the GBS infusion. INDO presumably has a beneficial effect in sepsis by inhibiting eicosanoid production. INDO does not affect endotoxin-induced TNF production in mice (17, 18) and did not significantly reduce GBS-induced TNF polypeptide levels in piglets. The beneficial effects of PTF+INDO pretreatment on GBS-induced late-phase features were greater than would be predicted from the effects of pretreatment with PTF or INDO alone. We speculate that the late phase of GBS sepsis in animal models is the most clinically relevant and the marked attenuation of the late-phase features by PTF+INDO is a new observation. The presumed mechanisms for PTF+INDO treatment improving Paol values during GBS sepsis include I ) attenuating the decline in CO with resultant increases in mixed venous oxygen pressure (6) and 2) reducing ventilation-perfusion mismatching due to inhibition of vasoactive mediators (6) . PTF+INDO treatment caused a greater reduction in PVR than SVR during both the acute and late phases of GBS sepsis. PTF causes preferential vasodilation of either the pulmonary or systemic vascular bed, depending upon which is the most constricted before treatment (36). We speculate that the preferential pulmonary vasodilation by PTF+INDO is due to the relatively greater GBS-induced increase in PVR compared with SVR. PTF+INDO prevented the GBS-induced fall in CO at 1 and 2 h by attenuating the decline in stroke volume (data not shown); however, PTF+INDO did not prevent the decline in P, at 4 h and only attenuated the reduction in CO and stroke volume (data not shown) at 4 h. The three groups of piglets showed a similar degree of tachycardia at 4 h of GBS infusion (data not shown). The fall in CO at 4 h may in part reflect the untoward vasodilatory properties of PTF at a dose of 20 mg/kg/h or potential negative inotropic effects of GBS. However, PTF infusion (20 mg/kg/h) into control piglets caused no fall in CO or Pa (8) .
Vasoactive arachidonic acid metabolites are important mediators in models of gram-negative and GBS sepsis (4) (5) (6) (7) (8) (9) (19) (20) (21) 226 GIBSON ET AL. and in some models of TNF,-induced shock (22, 23). INDO, ibuprofen, and combined lipoxygenase and cyclooxygenase inhibitors ameliorate endotoxin-induced shock (17, 18, 21) . INDO treatment blocks the GBS-induced late-phase decline in P, , but not late-phase GBS-induced pulmonary hypertension (5) . Dazmegrel, a thromboxane synthase inhibitor, reverses GBS-induced pulmonary hypertension up to 2 h after the onset of infusion, but was not tested at 4 h into GBS infusion when there were greater increases in serum TNF, levels (9) . There are discrepant reports on the effect of these drugs on the attenuation of TNF,-induced shock (1 8,23,24) . Some investigators report that INDO only attenuates endotoxin effects and has no influence on combined endotoxin-and TNF,-induced shock (24). There is less information available on the role of eicosanoids in TNF,-induced pulmonary hypertension (22, 25) . Recombinant human-TNF, infusion in piglets induced sustained pulmonary hypertension; pretreatment with dazmegrel inhibited the rise in P,, up to 30 min after the onset of TNF, infusion, but did not blunt a later phase of TNF,-induced pulmonary hypertension (25). Bacterialor TNF,-induced eicosanoids are important mediators of the hemodynamic and gas exchange abnormalities of sepsis, but inhibition of arachidonic acid metabolities alone is not sufficient to attenuate all the effects of TNF, or sepsis.
TNF, is an important mediator of gram-negative and grampositive septic shock (8, 10, 22, (26) (27) (28) . Pretreatment with anti-TNF, antibody prevented septic shock in a primate model of lethal gram-negative bacteremia (26); inhibition of serum TNF, production by pentoxifylline significantly improved survival in a murine model of endotoxic shock (15) . However, in a model of gram-negative pneumonia, anti-TNF, antibody neutralized lung lavage TNF, levels and blunted pulmonary antibacterial defenses (29). Therefore, although the attenuation of the systemic TNF, response may be beneficial, altering local TNF, production at inflammatory sites may have some deleterious effects (29, 30) . However, other studies suggest that TNF, alone cannot mimic the features of septic shock (24). TNF, may need to interact with bacterial products or other vasoactive mediators to cause untoward effects (17, 22-24, 31, 32) . TNF, can act synergistically with IL-1 (3 1) or with gram-negative or gram-positive bacterial products in the induction of shock in animal models (24, 32) . There is no direct evidence that TNF, and eicosanoids act synergistically in the pathophysiology of sepsis, but this possibility seems reasonable based on our observations that PTF+INDO pretreatment caused marked attenuation of GBS-induced late features compared with the modest effects of INDO or PTF alone (8) .
The production and/or activity of TNF, and arachidonic acid metabolites is interrelated in adult animal models of sepsis (17, 18, 22, 23, 25, 3 1) . TNF, infusion can induce the synthesis of TxA2, PG12, PGE2, and leukotrienes (22,27); leukotriene Bq can augment alveolar macrophage production of TNF, in vitro (33).
Inhibition of thromboxane and prostaglandin production by ibuprofen or indomethacin ameliorates endotoxin-and TNF,-induced shock and lung injury in some adult animal models (1 7, 21, 23, 3 1) . In addition, dual inhibition of both cyclooxygenase and 5-lipoxygenase markedly attenuates serum TNF, levels and lethality in a murine model of endotoxic shock (18) . These observations also support the speculation for an additive or synergistic interaction between TNF, and arachidonic acid metabolites.
Serum TNF, polypeptide levels may overestimate in vivo TNF, bioactivity in piglets treated with PTF+INDO. GBS infusion in piglets induces TNF, bioactivity as assayed by the G929 cytotoxicity assay (8) . Piglets infused with GBS+PTF+INDO had significant attenuation of serum TNF, polypeptide levels at 4 h compared with GBS alone piglets, but it is uncertain how much residual TNF, bioactivity remained. To measure in vivo TNF, bioactivity, serum TNF, bioassays would need to be done in vitro at the same concentrations of PTF present in the plasma of treated piglets, and these were not performed in this study.
PTF inhibits TNF, production in vitro by 50% at a concentration of 5 pM (lo), but it required approximately 100-fold greater PTF concentrations to inhibit TNF,-induced L-929 cytotoxicity (1 1). PTF blood levels have not been reported in animal models of sepsis, and the PTF concentration necessary to inhibit TNF,-induced cardiopulmonary responses is uncertain. We speculate that PTF inhibits serum TNF, bioactivity in the GBS+PTF+INDO group to a greater degree than suggested by the serum TNF, polypeptide levels (1 1, 15) , and this could partially explain the beneficial effects of PTF treatment of GBS sepsis. The beneficial effects of PTF+INDO treatment in the pigIet model of GBS sepsis may be due to factors other than the inhibition of thromboxane, prostacyclin, and TNF,. PTF attenuates TNF, production and TNF,-induced lung injury (8, (10) (11) (12) (13) (14) (15) , but has multiple additional effects in adult animals that could improve the untoward effects of GBS sepsis. These include I) decreased sepsis-induced lung injury (12) , 2) attenuation of TNF,-and endotoxin-induced endothelial cell injury in vitro (34, 35) , 3 ) decreased neutrophil sequestration in the lung (13), 4) vasodilatory properties, including the attenuation of hypoxic pulmonary vasoconstriction (36, 37), and 5) reduced blood viscosity (37). It is uncertain if all of these PTF effects are due to the inhibition of TNF,. There are no published reports on the effect of PTF treatment on either TNF,-or TxAz-induced pulmonary vasoconstriction. However, preliminary data from our laboratory show that PTF attenuates acute (<30 min) pulmonary hypertension in piglets infused with human recombinant TNF, (38). INDO inhibits thromboxane and prostaglandin synthesis by inhibition of cyclooxygenase, but in some species, or at high concentrations, also inhibits phospholipase Az, the initial enzymatic step in eicosanoid metabolism (39). Additional eicosanoids, such as leukotrienes, not measured in this study, but potentially inhibited by INDO, may contribute to the untoward effects of GBS sepsis. There are indirect data that leukotrienes are not important in the acute phase of GBS sepsis (20), but there are no data on the role of leukotrienes in the late phase of GBS sepsis. Finally, GBS sepsis probably stimulates additional proinflammatory and vasoactive mediators, not measured in this study, that may be inhibited by PTF or INDO treatment. For example, GBS induces the production of additional cytokines in vitro, such as IL1-6 (40), which if induced in vivo could act synergistically with TNF, to cause hemodynamic alterations and lung injury (3 1) . GBS may also cause hypoxemia and pulmonary hypertension by granulocyte-or complement-mediated pulmonary vascular injury (4 1, 42 hypertension.
